Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Expands Pharmaceutical Pipeline With $3.7 Bil Kos Acquisition

Executive Summary

Abbott's proposed $3.7 bil. acquisition of Kos Pharmaceuticals will help diversify Abbott's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases
Advertisement

Related Content

Lilly Expects Experience To Help Avoid Mistakes Of Pfizer’s Exubera Launch
Lilly Expects Experience To Help Avoid Mistakes Of Pfizer’s Exubera Launch
Abbott Cardiovascular Franchise Swells; Combo Waves Will Crest in 2009
Abbott Gears Up For New Cholesterol Therapies, Winds Down Diagnostics
Abbott closes Kos acquisition
Schering Tries To Lower Merck HDL Agent Expectations, Without Razing JV
Pfizer Exubera Has Mid-Year Launch Trigger, Heavy Dose Of Instructions
Pfizer Exubera Has Mid-Year Launch Trigger, Heavy Dose Of Instructions
Inhaled Insulin Manufacturers Find Size Matters After Exubera Cmte. Review
Abbott Sees Metabolic Growth In Knoll: Meridia May Mesh With TriCor
Advertisement
UsernamePublicRestriction

Register

PS047741

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel